🇺🇸 FDA
Patent

US 11268065

Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

granted A61KA61K2039/505A61K2039/804

Quick answer

US patent 11268065 (Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene) held by Precision BioSciences, Inc. expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Precision BioSciences, Inc.
Grant date
Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505, A61K2039/804, A61K2239/31, A61K2239/38